This trial is active, not recruiting.

Conditions cardiomyopathy, coronary artery disease
Sponsor Royal Brompton & Harefield NHS Foundation Trust
Start date January 2000
End date April 2015
Trial size 3000 participants
Trial identifier NCT00930735, 09/0904


The presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure

Clinical significance Correlation with biomarkers and genetic markers

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Groups with none and variable amounts of myocardial fibrosis

Primary Outcomes

All cause mortality
time frame: 3 years
Ventricular arrhythmias
time frame: 3 years
Unplanned heart failure admissions
time frame: 3 years

Secondary Outcomes

Ejection fraction
time frame: 3
NYHA status
time frame: 3

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - presence of an ischaemic or non-ischaemic cardiomyopathic process - no contraindication to contrast enhanced CMR - GFR >30 Exclusion Criteria: - ESRF - Contraindication to CM R

Additional Information

Official title The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy
Principal investigator Sanjay K Prasad, MD
Description Patients will undergo cardiovascular magnetic resonance (CMR) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via STIR sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)
Trial information was received from ClinicalTrials.gov and was last updated in February 2015.
Information provided to ClinicalTrials.gov by Royal Brompton & Harefield NHS Foundation Trust.